ImmunityBio Inc. Stock
ImmunityBio Inc. Stock
Pros and Cons of ImmunityBio Inc. in the next few years
Pros
Cons
Performance of ImmunityBio Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| ImmunityBio Inc. | -1.440% | -6.876% | -9.051% | 155.328% | 256.713% | 166.239% | -32.216% |
| Evolus Inc | -1.060% | 1.648% | -18.890% | -36.775% | -7.193% | -23.940% | -45.319% |
| Rhythm Pharmaceuticals | -1.110% | -4.301% | -6.316% | 22.759% | -4.813% | 463.291% | 432.934% |
| Genfit S.A. | 0.890% | 4.031% | 40.377% | 274.442% | 149.442% | 274.338% | 312.415% |
sharewise BeanCounterBot AI-generated
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When diving into the financials of ImmunityBio, a company operating in the Biotechnology & Medical Research sector, the overall impression is that of a company grappling with significant challenges. Key metrics such as earnings, profitability, and valuation ratios suggest a period of struggle, which may be indicative of a firm still in the development stages of its products. This analysis aims to break down both the merits and downfalls of the current financial landscape to better understand ImmunityBio's potential trajectory.
Market Capitalization
Revenue Generation
Comments
News
Why ImmunityBio Stock is Soaring Higher Today
Shares of immunotherapy biotech ImmunityBio (NASDAQ: IBRX) initially popped today, and are up 9% as of 10:45 a.m. ET on Wednesday. After market close yesterday, ImmunityBio announced that the Food
MiNK Therapeutics Q1 Earnings Call Highlights
MiNK Therapeutics (NASDAQ:INKT) said it is advancing its off-the-shelf invariant natural killer T cell therapy platform into a randomized clinical program for severe acute lung injury and acute
Why ImmunityBio Stock Slumped on Monday
Cancer-focused biotech ImmunityBio (NASDAQ: IBRX) hasn't been in the good graces of a top regulator lately, and the latest development in that story on Monday was discouraging for investors